Boston Scientific said it will appoint Joseph M. Fitzgerald as executive vice president and chief operating officer, effective Jan. 1, 2027, a move that also triggers a restructuring into three reportable segments.
The company said Fitzgerald will oversee global operations, business units and regions. He currently serves as executive vice president and group president, cardiovascular.
Under the new structure, Boston Scientific will report three segments starting Jan. 1:
- Interventional Therapies
- Rhythm Solutions
- Medsurg
The company said the change is intended to increase efficiency, speed decision-making and support capital allocation across the portfolio.
Leadership of the new segments will be divided as follows:
- Lance Bates will lead Interventional Therapies, which will include the Penumbra business once that acquisition closes.
- Nick Spadea-Anello will lead Rhythm Solutions.
- Stephen Morse will lead Medsurg and Asia Pacific.
Boston Scientific said the new structure reflects the current scale of the business and its expansion across cardiovascular, electrophysiology, Watchman, cardiac rhythm management and diagnostics, endoscopy, urology and neuromodulation.
The company said Fitzgerald’s appointment follows a period in which it has strengthened its portfolio through organic innovation, strategic investments and commercial execution. Today the company's shares have moved -0.49% to a price of $42.19. If you want to know more, read the company's complete 8-K report here.
